{"id":35563,"date":"2020-08-21T00:28:10","date_gmt":"2020-08-20T16:28:10","guid":{"rendered":"https:\/\/case.ntu.edu.tw\/blog\/?p=35563"},"modified":"2020-08-21T09:32:49","modified_gmt":"2020-08-21T01:32:49","slug":"%e5%9f%ba%e5%9b%a0%e7%b7%a8%e8%bc%af%e6%8a%80%e8%a1%93-crispr-%e5%8f%af%e4%bb%a5%e5%b0%8d%e6%8a%97-covid-19%ef%bc%9f","status":"publish","type":"post","link":"https:\/\/case.ntu.edu.tw\/blog\/?p=35563","title":{"rendered":"\u57fa\u56e0\u7de8\u8f2f\u6280\u8853 CRISPR \u53ef\u4ee5\u5c0d\u6297 COVID-19\uff1f"},"content":{"rendered":"
\"\"
\u5716\u7247\u4f86\u6e90: pixabay<\/figcaption><\/figure>\n

COVID-19\u7684\u5927\u6d41\u884c\u51f8\u986f\u5728\u7121\u6709\u6548\u75ab\u82d7\u53ca\u6cbb\u7642\u85e5\u7269\u7684\u60c5\u6cc1\u4e0b\uff0c\u767c\u5c55\u65b0\u8208\u6297\u75c5\u6bd2\u65b9\u6cd5\u7684\u91cd\u8981\u6027\u3002\u5df2\u6709\u7814\u7a76\u986f\u793a\u57fa\u65bcCRISPR\/Cas13\u7b56\u7565\u7684\u4eba\u9ad4\u7d30\u80de\u7684\u9810\u9632\u6027\u6297\u75c5\u6bd2CRISPR\uff08PAC-MAN\uff09\u53ef\u4ee5\u5728\u7d30\u80de\u57f9\u990a\u4e2d\u6709\u6548\u6291\u5236SARS-CoV-2\uff0c\u85c9\u7531\u8a2d\u8a08\u548c\u7be9\u9078\u6a19\u9776\u4f5c\u7528\u65bc\u75c5\u6bd2\u57fa\u56e0\u9ad4\u4fdd\u5b88\u5340\u57df\u7684CRISPR RNA\uff08crRNA\uff09\uff0c\u53ef\u4ee5\u6709\u6548\u6a19\u9776\u4f5c\u7528\u4e26\u5207\u5272 SARS-CoV-2\u7684RNA\u5e8f\u5217\uff0c\u986f\u8457\u6291\u5236\u75c5\u6bd2\u751f\u9577\uff0c\u751f\u7269\u8cc7\u8a0a\u7684\u5206\u6790\u7d50\u679c\u5247\u986f\u793a\u67096\u500bcrRNA\u53ef\u6a19\u9776\u4f5c\u7528\u8d85\u904e90\uff05\u7684\u51a0\u72c0\u75c5\u6bd2\u3002\u82e5\u80fd\u89e3\u6c7a\u50b3\u905e\u5de5\u5177\u9078\u64c7\u53ca\u5b89\u5168\u6027\u9867\u616e\u7684\u554f\u984c\uff0cPAC-MAN\u6709\u53ef\u80fd\u6210\u70ba\u5c0d\u6297COVID-19\u7684\u6709\u6548\u7b56\u7565\u4e4b\u4e00\u3002<\/strong><\/span><\/p>\n

\u64b0\u6587\uff0f\u9673\u6df5\u9293<\/strong><\/p>\n

\u25cfCRISPR<\/strong>\u7528\u65bc\u5c0d\u6297\u75c5\u6bd2<\/strong><\/span><\/p>\n

\u53e2\u96c6\u7684\u898f\u5247\u9593\u9694\u7684\u77ed\u8ff4\u6587\u91cd\u8907\u5e8f\u5217\uff08clustered regularly interspaced short palindromic repeats, CRISPR\uff09\/ CRISPR\u76f8\u95dc\u86cb\u767d\uff08CRISPR associated protein, Cas\uff09\uff08CRISPR\/Cas\uff09\u7cfb\u7d71\u662f\u4e00\u7a2e\u88ab\u5ee3\u6cdb\u61c9\u7528\u7684\u57fa\u56e0\u7de8\u8f2f\u6280\u8853\uff0c\u4e26\u5df2\u6210\u529f\u5728\u6d3b\u9ad4\u5916\uff08in vitro\uff09\u53ca\u52d5\u7269\u5be6\u9a57\u4e2d\u4f5c\u70ba\u6297\u75c5\u6bd2\u7b56\u7565\u7528\u65bc\u6e05\u9664\u591a\u7a2e\u75c5\u6bd2\uff0c\u5982B\u578b\u809d\u708e\u75c5\u6bd2\uff08hepatitis B virus, HBV\uff09\u3001\u9f3b\u54bd\u75c5\u6bd2\uff08Epstein-Barr, EBV\uff09\u3001\u611b\u6ecb\u75c5\u6bd2\uff08human immunodeficiency virus, HIV)\u3001\u5de8\u7d30\u80de\u75c5\u6bd2\uff08cytomegalovirus, CMV\uff09\u3001\u7c21\u55ae\u76b0\u75b9\u75c5\u6bd2\u7b2c\u4e00\u578b\uff08herpes simplex virus-1, HSV-1\uff09\u53ca\u4eba\u985e\u4e73\u7a81\u75c5\u6bd2\uff08human papillomavirus, HPV)\u7b49\u3002\u56e0\u6b64\uff0cCRISPR\u4ea6\u6709\u6f5b\u529b\u958b\u767c\u4f5c\u70ba\u6cbb\u7642COVID-19\u7684\u65b0\u578b\u6297\u75c5\u6bd2\u7b56\u7565\u3002<\/p>\n

\u25cf\u958b\u767c<\/strong>CRISPR<\/strong>\u4f5c\u70ba\u5c0d\u6297<\/strong> COVID-19<\/strong>\u7684\u7b56\u7565<\/strong><\/span><\/p>\n

\u5728 2020\u5e74\uff0c\u7f8e\u570b\u7814\u7a76\u4eba\u54e1\u8a2d\u8a08\u4e26\u7be9\u9078\u4e86CRISPR RNA\uff08crRNA\uff09\u6a19\u9776\u4f5c\u7528\u65bc\u75c5\u6bd2\u57fa\u56e0\u9ad4\u7684\u4fdd\u5b88\u5340\u57df\uff0c\u4e26\u9451\u5b9a\u4e86\u4eba\u5728\u985e\u80ba\u90e8\u4e0a\u76ae\u7d30\u80de\uff08A549 \u7d30\u80de\u682a\uff09\u57f9\u990a\u4e2d\u6a19\u9776\u4f5c\u7528\u5230\u65b0\u578b\u51a0\u72c0\u75c5\u6bd2\uff08SARS-CoV-2\uff09\u548cA\u578b\u6d41\u884c\u6027\u611f\u5192\u75c5\u6bd2\uff08Influenza A virus subtype, H1N1 IAV<\/em>\uff09<\/em>\u7684\u529f\u80fd\u6027crRNA\u3002\u4eba\u985e\u7d30\u80de\u7684\u9810\u9632\u6027\u6297\u75c5\u6bd2CRISPR\uff08prophylactic antiviral CRISPR in human cells, PAC-MAN\uff09\u662f\u4e00\u7a2e\u6839\u64daCRISPR \/ Cas13\u7684\u6297\u75c5\u6bd2\u7b56\u7565\uff0c\u4ed6\u5011\u7684\u5be6\u9a57\u7d50\u679c\u767c\u73feCas13d PAC-MAC\u53ef\u6709\u6548\u5730\u6a19\u9776\u4f5c\u7528\u548c\u5207\u5272 SARS-CoV-2\u7684RNA\u5e8f\u5217\uff0c\u800c\u4e14\u53ef\u4ee5\u6e1b\u5c11\u547c\u5438\u9053\u611f\u67d3\u7684H1N1 IAV\u7684\u75c5\u6bd2<\/em>\u8ca0\u8f09\u91cf\uff08viral load\uff09\uff0c\u986f\u8457\u6291\u5236\u75c5\u6bd2\u7684\u751f\u9577\u3002\u53e6\u5916\uff0c\u751f\u7269\u8cc7\u8a0a\u5b78\u7684\u5206\u6790\u986f\u793a\u67096\u7a2ecrRNA\u53ef\u4ee5\u6a19\u9776\u4f5c\u7528\u523090\uff05\u4ee5\u4e0a\u7684\u51a0\u72c0\u75c5\u6bd2\uff0c\u800c\u4e14PAC-MAN\u6e1b\u5c11\u4e86\u7d0490\uff05\u7684\u75c5\u6bd2\u8ca0\u8f09\u91cf\uff0c\u4e26\u53ef\u6a19\u9776\u4f5c\u7528\u591a\u7a2e\u75c5\u6bd2\uff0c\u4f46\u76ee\u524d\u6b64\u7814\u7a76\u50c5\u5728\u7d30\u80de\u57f9\u990a\u4e2d\u9032\u884c\uff0c\u9700\u8981\u9032\u884c\u6d3b\u9ad4\u5167\u5be6\u9a57\u548c\u9032\u4e00\u6b65\u7684\u81e8\u5e8a\u8a66\u9a57\u65b9\u80fd\u9a57\u8b49CRISPR\u7684\u6548\u7528\u3002<\/p>\n

\u25cf\u767c\u5c55\u524d\u666f\u53ca\u6280\u8853\u9650\u5236<\/strong><\/span><\/p>\n

\u57fa\u56e0\u6a19\u9776\u6280\u8853\uff08\u5982CRISPR\uff09\u7684\u767c\u5c55\u8fc5\u901f\uff0c\u4f5c\u7528\u5c08\u4e00\u6027\u53ca\u4fb7\u9650\u6027\u7684\u554f\u984c\u5df2\u5927\u5e45\u6539\u5584\uff0cCRISPR\u56e0\u5177\u6709\u53ef\u56e0\u61c9\u75c5\u6bd2\u9ad8\u8b8a\u7570\u6027\u800c\u81ea\u884c\u8a2d\u8a08\u5408\u6210\u6838\u9178\u5e8f\u5217\u7684\u7279\u9ede\uff0c\u4f7f\u5f97PAC-MAN\u78ba\u5be6\u5177\u6709\u6f5b\u529b\u6210\u70ba\u963b\u65b7\u75c5\u6bd2\u8907\u88fd\u548c\u57fa\u56e0\u8868\u73fe\u7684\u65b9\u6cd5\u3002\u4f7f\u7528CRISPR\/Cas13d\u5c0d\u6297\u51a0\u72c0\u75c5\u6bd2\u4ee5\u4fdd\u8b77\u4eba\u9ad4\u7d30\u80de\u514d\u53d7\u611f\u67d3\u6216\u6e05\u9664\u53d7\u5230\u611f\u67d3\u4e4b\u7d30\u80de\u5167\u7684\u75c5\u6bd2\uff0c\u5c07\u53ef\u80fd\u63d0\u4f9b\u4e00\u7a2e\u53d6\u4ee3\u50b3\u7d71\u6297\u75c5\u6bd2\u85e5\u7269\u7684\u66ff\u4ee3\u6027\u6216\u88dc\u5145\u7684\u6cbb\u7642\u7b56\u7565\uff08alternative or additional therapeutic strategy\uff09\u3002<\/p>\n

\u7136\u800c\uff0c\u5728\u81e8\u5e8a\u61c9\u7528\u4e2d\u4f7f\u7528PAC-MAN\u9084\u5b58\u5728\u4e00\u4e9b\u6280\u8853\u9650\u5236\u5982\u4e0b\uff1a\uff081\uff09PAC-MAN\u4ee5\u7d30\u80de\u81ea\u4e3b\u65b9\u5f0f\u767c\u63ee\u4f5c\u7528\uff0c\u986f\u793a\u50c5\u6709\u53ef\u4ee5\u8868\u9054Cas13d\u548ccrRNA\u7684\u7d30\u80de\u53ef\u4ee5\u76f4\u63a5\u5c0d\u6297\u6a19\u7684\u75c5\u6bd2\u3002\uff082\uff09\u70ba\u78ba\u4fddPAC-MAN\u5c0d\u60a3\u8005\u6709\u6548\uff0c\u9700\u8981\u5728\u4e00\u5b9a\u6bd4\u4f8b\u7684\u7d30\u80de\u4e2d\u5145\u5206\u8868\u73fePAC-MAN\uff0c\u5176\u7bc4\u570d\u9700\u7d93\u7531\u66f4\u591a\u9032\u4e00\u6b65\u7684\u5be6\u9a57\u52a0\u4ee5\u78ba\u8a8d\u3002\uff083\uff09\u7531\u65bccrRNA\u7684\u8868\u73fe\u5728SARS-CoV-2\u5e8f\u5217\u7684\u5207\u5272\u6548\u7387\u4e0a\u626e\u6f14\u4e86\u95dc\u9375\u7684\u89d2\u8272\uff0c\u6545\u8abf\u7bc0\u7d30\u80de\u4e2dCas13d\u6c34\u5e73\u53ca\u5176\u540c\u6e90crRNA\u7684\u80fd\u529b\uff0c\u5c0d\u65bc\u6709\u6548\u6291\u5236\u75c5\u6bd2\u5341\u5206\u91cd\u8981\u3002\uff084\uff09\u7531\u65bcSARS-CoV-2 \u7684RNA\u57fa\u56e0\u7d44\u5448\u73fe\u4e8c\u7d1a\u7d50\u69cb\uff08secondary structure\uff09\u6216\u88ab\u4fdd\u8b77\u6027\u86cb\u767d\u8986\u84cb\uff0c\u6545\u75c5\u6bd2\u53ef\u80fd\u4e0d\u6613\u88ab\u6291\u5236\uff0c\u6240\u4ee5\u9808\u5c0dcrRNA\u9032\u884c\u666e\u904d\u7be9\u9078\u624d\u6709\u52a9\u65bc\u9451\u5b9a\u51fa\u6a19\u9776\u4f5c\u7528\u5230\u6d3bSARS-CoV-2\u7684\u9ad8\u6548\u7387crRNA\u3002<\/p>\n

\u25cf\u81e8\u5e8a\u61c9\u7528\u9762\u81e8\u7684\u6311\u6230<\/strong><\/span><\/p>\n

\u5728\u5148\u524d\u7684\u7814\u7a76\u4e2d\uff0c\u5df2\u6709\u8a31\u591aCRISPR\u6210\u529f\u7528\u65bc\u6291\u5236\u75c5\u6bd2\u88c2\u89e3\u6027\u8907\u88fd\uff08lytic replication\uff09\u548c\/\u6216\u6e05\u9664\u6f5b\u4f0f\u6027\u611f\u67d3\uff08latent infection\uff09\u7684\u5831\u544a\u3002\u4f46\u9019\u4e9b\u90fd\u53ea\u662f\u5728\u6d3b\u9ad4\u5916\u548c\/\u6216\u6d3b\u9ad4\u5167\uff08in vivo\uff09\u7814\u7a76\uff0c\u771f\u6b63\u9032\u5165\u4eba\u9ad4\u81e8\u5e8a\u8a66\u9a57\u8005\u4ecd\u4ed8\u4e4b\u53a5\u5982\uff0cCRISPR\u8981\u61c9\u7528\u5728\u81e8\u5e8a\u75c5\u4eba\u8eab\u4e0a\u4ecd\u6709\u95dc\u9375\u6027\u6311\u6230\u5982\u4e0b\uff1a<\/p>\n

1.\u50b3\u905e\u5de5\u5177\uff08delivery tool\uff09\u7684\u9078\u64c7\uff1a\u50b3\u905e\u5de5\u5177\u662f\u4e00\u7a2e\u7528\u4ee5\u4fc3\u9032\u6838\u9178\uff08nucleic acid\uff09\u9032\u5165\u6a19\u7684\u7d30\u80de\u7684\u56e0\u5b50\uff0c\u4e3b\u8981\u7684\u529f\u7528\u662f\u589e\u52a0DNA\uff08\u5982\u57fa\u56e0\u3001DNA\u7247\u6bb5\u53ca\u8cea\u9ad4 DNA\uff09\u6216RNA\uff08\u5982mRNA<\/a>\u3001 miRNA\u53casiRNA<\/a>\uff09\u7684\u8f49\u67d3\uff08transfection\uff09\u6548\u7387\u3002\u76ee\u524d\u5df2\u6709\u591a\u7a2e\u50b3\u905e\u5de5\u5177\u958b\u767c\u6210\u529f\u7528\u65bc\u57fa\u790e\u7814\u7a76\uff0c\u5305\u62ec\u8102\u8cea\uff08lipoid\uff09\u3001\u75c5\u6bd2\uff08\u5982 lentivirus, adenovirus, adeno- associated virus, etc.\uff09\u3001\u5948\u7c73\u7c92\u5b50\uff08nanoparticle\uff09\u3001\u7d30\u83cc\uff08Salmonella<\/em>\uff09\u3001\u57fa\u56e0\u69cd\uff08gene gun\uff09\u3001\u96fb\u885d\u64ca\uff08electroporation\uff09\u53ca\u5948\u7c73\u5438\u7ba1\uff08nanostraw\uff09\u7b49\u3002CRISPR\u8981\u81e8\u5e8a\u61c9\u7528\u65bc\u4eba\u9ad4\u6cbb\u7642\uff0c\u9700\u6709\u9069\u7576\u7684\u50b3\u905e\u5de5\u5177\u4ee5\u904b\u9001 CRISPR\u5230\u9054\u6a19\u7684\u7d30\u80de\u6216\u75c5\u6bd2\u5165\u4fb5\u4e4b\u4f4d\u7f6e\uff0c\u4f46\u8981\u9078\u64c7\u4e00\u7a2e\u517c\u5177\u5c08\u4e00\u3001\u5b89\u5168\u53ca\u9ad8\u6548\u7387\u7684\u50b3\u905e\u5de5\u5177\u5341\u5206\u56f0\u96e3\uff0c<\/p>\n

2.\u5b89\u5168\u6027\u9867\u616e: CRISPR\u4f5c\u7528\u65bc\u6a19\u7684\u57fa\u56e0\u6642\u6703\u56e0\u7522\u751f\u812b\u9776\u6548\u61c9\uff08off target effect\uff09\uff0c\u800c\u9020\u6210\u4e0d\u53ef\u9810\u6e2c\u7684\u8b8a\u7570\uff0c\u96d6\u7136\u73fe\u5728\u7684\u6280\u8853\u5df2\u53ef\u5927\u5e45\u964d\u4f4e\u5176\u767c\u751f\u7684\u6bd4\u7387\uff0c\u4f46\u5b8c\u5168\u907f\u514d\u4ecd\u662f\u4e0d\u53ef\u80fd\u7684\u3002\u812b\u9776\u6548\u61c9\u5728\u7d30\u80de\u53ca\u52d5\u7269\u5be6\u9a57\u6642\uff0c\u53ea\u8981\u59a5\u5584\u8655\u7406\u6b64\u7a2e\u8b8a\u7570\u7d30\u80de\u6216\u52d5\u7269\u5373\u53ef\uff0c\u4f46\u61c9\u7528\u5728\u4eba\u9ad4\u6cbb\u7642\u6642\uff0c\u5fc5\u9808\u8003\u91cf\u4e0d\u6703\u50b7\u5bb3\u5230\u6b63\u5e38\u7684\u7d30\u80de\u53ca\u5065\u5eb7\u7684\u7d44\u7e54\uff0c\u842c\u4e00\u5f15\u8d77\u7a81\u8b8a\u751a\u81f3\u81f4\u764c\uff0c\u9020\u6210\u7684\u50b7\u5bb3\u548c\u5f8c\u679c\u5c07\u96e3\u4ee5\u88dc\u6551\u3002\u56e0\u6b64\uff0c\u589e\u5f37CRISPR\u4f5c\u7528\u7684\u5c08\u4e00\u6027\u6975\u70ba\u91cd\u8981\uff0c\u5982\u4f55\u50c5\u6bba\u6b7b\u5165\u4fb5\u7684\u75c5\u6bd2\u800c\u4e0d\u50b7\u5bb3\u4eba\u9ad4\u662f\u95dc\u9375\u6027\u7684\u8ab2\u984c\u3002<\/p>\n

\u5728\u9032\u884c\u81e8\u5e8a\u8a66\u9a57\u4e4b\u524d\uff0c\u5fc5\u9808\u9078\u64c7\u9069\u7576\u7684\u50b3\u905e\u5de5\u5177\u4ee5\u78ba\u4fdd\u50b3\u9001CRISPR\u6642\u7684\u5c08\u4e00\u6027\u3001\u5b89\u5168\u6027\u53ca\u9ad8\u6548\u7387\uff0c\u4e26\u6392\u9664\u812b\u9776\u6548\u61c9\u53ef\u80fd\u5f15\u8d77\u7684\u7a81\u8b8a\u6216\u816b\u7624\u767c\u751f\u7684\u98a8\u96aa\u3002\u5982\u679c\u9019\u4e9b\u969c\u7919\u53ef\u4ee5\u514b\u670d\uff0c\u90a3\u9ebc\u76f8\u5c0d\u65bc\u50b3\u7d71\u7684\u6297\u75c5\u6bd2\u85e5\u7269\u800c\u8a00\uff0c\u4f7f\u7528PAC-MAN\u7b56\u7565\u61c9\u7528\u65bcCOVID-19\u7684\u4eba\u9ad4\u6cbb\u7642\u5c31\u80fd\u986f\u73fe\u7368\u7279\u7684\u512a\u9ede\u53ca\u6cbb\u7642\u5229\u76ca\u3002<\/p>\n

 <\/p>\n

\u53c3\u8003\u8cc7\u6599\uff1a<\/strong><\/p>\n

    \n
  1. Abbott<\/a> TR, Dhamdhere<\/a> G, Liu<\/a> Y, Lin<\/a> X, Goudy<\/a> L, Zeng<\/a> L, Chemparathy<\/a> A, Chmura<\/a> S, Heaton<\/a> NS, Debs<\/a> R, Pande<\/a> T, Endy<\/a> D, Russa<\/a> MFL, Lewis<\/a> DB, Q<\/a>I LS. Development of CRISPR as an antiviral strategy to combat SARS-CoV-2 and influenza. Cell 2020,<\/strong> 81(4):865-876.e12. doi: 10.1016\/j.cell.2020.04.020. Epub 2020 Apr 29.<\/li>\n
  2. Luther DC, Lee YW, Nagaraj H, Scaletti F, Rotello VM. Delivery approaches for CRISPR\/Cas9 therapeutics in vivo: advances and challenges. Expert Opin Drug Deliv.<\/em> 2018, 15(9):905-913. doi: 10.1080\/17425247.2018.1517746. Epub 2018 Sep 12.<\/li>\n
  3. Lino CA, Harper, JC, Carney JP, Timlin JA. Delivering CRISPR: a review of the challenges and approaches. Drug Deliv.<\/em> 2018, 25(1):1234-1257. doi: 10.1080\/10717544.2018.1474964.<\/li>\n
  4. Rodr\u00edguez-Rodr\u00edguez DR, Ram\u00edrez-Sol\u00eds R, Garza-Elizondo MA, Garza-Rodr\u00edguez ML, Barrera-Salda\u00f1a HA. Genome editing: A perspective on the application of CRISPR\/Cas9 to study human diseases (Review). Int J Mol Med. 2019 Apr;43(4):1559-1574.doi: 10.3892\/ijmm.2019.4112.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    COVID-19\u7684\u5927\u6d41\u884c\u51f8\u986f\u5728\u7121\u6709\u6548\u75ab\u82d7\u53ca\u6cbb\u7642\u85e5\u7269\u7684\u60c5\u6cc1\u4e0b\uff0c\u767c\u5c55\u65b0\u8208\u6297\u75c5\u6bd2\u65b9\u6cd5\u7684\u91cd\u8981\u6027\u3002\u5df2\u6709\u7814\u7a76\u986f\u793a\u57fa\u65bcCRISPR\/Cas13\u7b56\u7565\u7684\u4eba\u9ad4\u7d30\u80de\u7684\u9810\u9632\u6027\u6297\u75c5\u6bd2CRISPR\uff08PAC-MAN\uff09\u53ef\u4ee5\u5728\u7d30\u80de\u57f9\u990a\u4e2d\u6709\u6548\u6291\u5236SARS-CoV-2\uff0c\u85c9\u7531\u8a2d\u8a08\u548c\u7be9\u9078\u6a19\u9776\u4f5c\u7528\u65bc\u75c5\u6bd2\u57fa\u56e0\u9ad4\u4fdd\u5b88\u5340\u57df\u7684CRISPR RNA\uff08crRNA\uff09\uff0c\u53ef\u4ee5\u6709\u6548\u6a19\u9776\u4f5c\u7528\u4e26\u5207\u5272 SARS-CoV-2\u7684RNA\u5e8f\u5217\uff0c\u986f\u8457\u6291\u5236\u75c5\u6bd2\u751f\u9577\uff0c\u751f\u7269\u8cc7\u8a0a\u7684\u5206\u6790\u7d50\u679c\u5247\u986f\u793a\u67096\u500bcrRNA\u53ef\u6a19\u9776\u4f5c\u7528\u8d85\u904e90\uff05\u7684\u51a0\u72c0\u75c5\u6bd2\u3002\u82e5\u80fd\u89e3\u6c7a\u50b3\u905e\u5de5\u5177\u9078\u64c7\u53ca\u5b89\u5168\u6027\u9867\u616e\u7684\u554f\u984c\uff0cPAC-MAN\u6709\u53ef\u80fd\u6210\u70ba\u5c0d\u6297COVID-19\u7684\u6709\u6548\u7b56\u7565\u4e4b\u4e00\u3002<\/p>\n","protected":false},"author":20,"featured_media":35564,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4580,3293],"tags":[4577,3075,4705,4612],"aioseo_notices":[],"jetpack_featured_media_url":"https:\/\/case.ntu.edu.tw\/blog\/wp-content\/uploads\/2020\/08\/31351.jpg","_links":{"self":[{"href":"https:\/\/case.ntu.edu.tw\/blog\/index.php?rest_route=\/wp\/v2\/posts\/35563"}],"collection":[{"href":"https:\/\/case.ntu.edu.tw\/blog\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/case.ntu.edu.tw\/blog\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/case.ntu.edu.tw\/blog\/index.php?rest_route=\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/case.ntu.edu.tw\/blog\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=35563"}],"version-history":[{"count":2,"href":"https:\/\/case.ntu.edu.tw\/blog\/index.php?rest_route=\/wp\/v2\/posts\/35563\/revisions"}],"predecessor-version":[{"id":35585,"href":"https:\/\/case.ntu.edu.tw\/blog\/index.php?rest_route=\/wp\/v2\/posts\/35563\/revisions\/35585"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/case.ntu.edu.tw\/blog\/index.php?rest_route=\/wp\/v2\/media\/35564"}],"wp:attachment":[{"href":"https:\/\/case.ntu.edu.tw\/blog\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=35563"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/case.ntu.edu.tw\/blog\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=35563"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/case.ntu.edu.tw\/blog\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=35563"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}